Economics of Beta-Cell Replacement Therapy
Purpose of Review: Type 1 diabetes impacts 1.3 million people in the USA with a total direct lifetime medical cost of $133.7 billion. Management requires a mix of daily exogenous insulin administration and frequent glucose monitoring. Decision-making by the individual can be burdensome. Recent Findi...
Main Authors: | , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
Springer Science and Business Media LLC
2020
|
Online Access: | https://hdl.handle.net/1721.1/128519 |